Table 2.
Comparisons between groups at the end of the study
|
BDP/F 400/24 μg/day (N = 206) |
FP/S 500/100 μg/day (N = 216) |
Between group p value |
|
|---|---|---|---|
| FEV1, L |
2.92 (0.04) |
2.92 (0.03) |
0.938 |
| FEV1% predicted |
85.90 (0.98) |
85.70 (0.98) |
0.878 |
| PEF, L/min |
442.47 (4.57) |
440.21 (4.55) |
0.699 |
| PEF % predicted |
96.87 (1.46) |
98.43 (1.32) |
0.428 |
| Daytime symptoms scorea |
1.37 (0.07) |
1.32 (0.06) |
0.609 |
| Night-time symptom scorea |
1.33 (0.11) |
1.46 (0.10) |
0.368 |
| symptom-free days, % |
93.66 (1.13) |
92.47 (1.11) |
0.451 |
| Controlled asthmab, n (%) |
163 (90.0) |
167 (85.2) |
0.362 |
| Partly controlled asthmab, % |
11 (6.0) |
18 (9.2) |
|
| Uncontrolled asthmab, % | 7 (4.0) | 11 (5.6) |
The values are adjusted means (SE). The lung function values were measured during the last visit. a the mean of the last 4 weeks of treatment derived from diary cards, b in the last 4 weeks of the treatment period. BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow.